Presentations will include an overview of the long-term corporate strategy, the global market opportunity in rare pediatric and adult liver disease, and the global commercialization strategy and launch readiness plans for odevixibat in progressive familial intrahepatic cholestasis (PFIC), an ultra-rare pediatric cholestatic liver disease.
The event will be hosted by
Commercial Day Call Details for
Conference ID: 13714756
Participant Webcast Link: http://public.viavid.com/index.php?id=142919
The virtual event will also be accessible from the Albireo Media and Investors page ir.albireopharma.com.
Albireo Pharma is a clinical-stage biopharmaceutical company focused on the development of novel bile acid modulators to treat rare pediatric and adult liver diseases, and other adult liver diseases and disorders. Albireo’s lead product candidate, odevixibat, is being developed to treat rare pediatric cholestatic liver diseases with Phase 3 pivotal trials in PFIC, Alagille syndrome and biliary atresia. The Company completed IND-enabling studies for new preclinical candidate A3907 this year and plans to advance development in adult liver disease. Albireo was spun out from AstraZeneca in 2008 and is headquartered in Boston, Massachusetts, with its key operating subsidiary in Gothenburg, Sweden. The Boston Business Journal named Albireo one of the 2020 Best Places to Work in Massachusetts for the second consecutive year. For more information on Albireo, please visit www.albireopharma.com.
Media & Investor contacts:
Source: Albireo Pharma, Inc.